Evidence map›Paper›PMID 39411694›Full record

ArticleAdvanced biomedical research2024

Cytotoxic Effects of a Novel tagged Apoptin on Breast Cancer Cell Lines.

Parisa Lakhshei, Shahrzad Ahangarzadeh, Fatemeh Yarian, Ameneh Koochaki, Bahram Kazemi, Zahra Kiamehr, Elmira Mohammadi, Abbas Alibakhshi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced biomedical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Parisa LakhsheiCellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahrzad AhangarzadehInfectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Fatemeh YarianDepartment of Medical Biotechnology, school of advanced technologies in medicine, Fasa University of Medical Sciences, Fasa, Iran.
Ameneh KoochakiDepartment of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Bahram KazemiCellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zahra KiamehrDepartment of Biochemistry, Faculty of Biological Science, North Tehran Branch, Islamic Azad University, Tehran, Iran.
Elmira MohammadiCore Research Facilities (CRF), Isfahan University of Medical Sciences, Isfahan, Iran.
Abbas AlibakhshiMolecular Medicine Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds: Apoptin can induce tumor cell-specific apoptosis in a broad range of human tumor cells and is a potential anticancer therapeutic candidate to kill tumor cells. Materials and Methods: We designed two structures of apoptin fusion protein, SUMO-PTD4-Apoptin, and PTD4-Apoptin. To express these fusion proteins, Results: Expression of the recombinant SUMO-PTD4-Apoptin and PTD4-Apoptin in Conclusion: This study demonstrates that the fusion of PTD4-Apoptin to SUMO-PTD4-Apoptin could provide an effective method to help enhance the expression and solubility of heterologous Apoptin in

Indexed as

Apoptinapoptosisbreast cancer

Identifiers

PMID39411694
PMCPMC11478704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.